Mild and Short Recurrence of Type II Amiodarone-induced Thyrotoxicosis in Three Patients Receiving Amiodarone Continuously for More Than 10 Years

• SATO Kanji

  Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University

• SHIGA Tsuyoshi

  Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University

• MATSUDA Naoki

  Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University

• ONODA Noritaka

  Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University

• TAKANO Kazue

  Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University

• HAGIWARA Nobuhisa

  Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University

• KASANUKI Hiroshi

  Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University

Abstract

Although there are two types of amiodarone-induced thyrotoxicosis (AIT), only type II AIT has been seen at our institution in Japan so far. There have been few case reports of AIT recurrence, probably because of the fact that amiodarone is immediately discontinued once AIT has developed. Our own policy is not to discontinue amiodarone in all AIT patients, unless severe adverse effects such as pulmonary fibrosis develop. Among more than 50 patients with type II AIT we have encountered, three with arrhythmogenic right ventricular cardiomyopathy showed AIT recurrence. In these patients, the first episode of AIT developed 3, 4, and 2 years after the start of amiodarone administration, and recurrence was observed 5, 6, and 8 years after the first episode, respectively. The AIT resolved spontaneously in all cases while the patients continued to take amiodarone. In comparison with the first AIT episode, the second was milder and resolved within a shorter period. These three cases suggest that recurrence of type II AIT may not be rare in iodine-sufficient areas, and that it is relatively mild and may resolve spontaneously. Furthermore, at least in Japan, it may be possible for patients with recurrent type II AIT to continue taking amiodarone.<br>

Journal

• Endocrine Journal

  Endocrine Journal 53 (4), 531-538, 2006

  The Japan Endocrine Society

Keywords

• Amiodarone
• Thyrotoxicosis
• Type II amiodarone-induced thyrotoxicosis
• Anti-thyroid hormone antibody

Details

• CRID: 1390282681277440000
• NII Article ID: 10019269869
• NII Article ID: 130004443254
• NII Book ID: AA10901436
• DOI: 10.1507/endocrj.k06-027
• COI: 1:CAS:528:DC%2BD28Xht1SgsLnO
• ISSN: 13484540
• ISSN: 09188959
• Web Site: http://www.jstage.jst.go.jp/article/endocrj/53/4/53_4_531/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2007071207
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed